SCHEMBL2409810

SCHEMBL2409810

O=c1c2c(Cc3ccccc3)n[nH]c2c2cccnc2n1-c1cccc(F)c1

nearest known ligand 0.55

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
PDE1A P54750 1/20 0.55
PDE1B Q01064 1/20 0.55
KMT2A Q03164 1/20 0.43
PARP1 P09874 5/20 0.41
PDE4A P27815 3/20 0.41
PDE4B Q07343 2/20 0.41
PDE4C Q08493 2/20 0.41
PDE4D Q08499 2/20 0.41
MAPT P10636 3/20 0.40
AR P10275 1/20 0.38
LMNA P02545 1/20 0.37
TP53 P04637 1/20 0.37
FEN1 P39748 1/20 0.37
REN P00797 1/20 0.37
ALDH1A1 P00352 1/20 0.36
TSHR P16473 1/20 0.36
CYP2C19 P33261 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2410839 0.90 PDE1A (0.66) PDE1APDE1BPARP1PDE4APDE4B
SCHEMBL2409264 0.89 PDE1A (0.58) PDE1APDE1BPARP1PDE4APDE4B
SCHEMBL2409464 0.89 PDE1A (0.55) PDE1APDE1BPARP1PDE4APDE4B
SCHEMBL4194544 0.88 PDE1A (0.52) PDE1APDE1BPARP1PDE4APDE4B
SCHEMBL2406533 0.87 PDE1A (0.53) PDE1APDE1BKMT2APARP1PDE4A
SCHEMBL4197165 0.86 PDE1A (0.51) PDE1APDE1BPARP1PDE4APDE4B
SCHEMBL2408000 0.86 PDE1A (0.52) PDE1APDE1BPARP1PDE4APDE4B
SCHEMBL2409224 0.85 PDE4A (0.52) PDE1APDE1BKMT2APARP1PDE4A
SCHEMBL2410462 0.85 PDE1A (0.55) PDE1APDE1BPARP1PDE4APDE4B
SCHEMBL2409546 0.85 PDE1A (0.55) PDE1APDE1BKMT2APARP1PDE4A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1559716-B1 PYRAZOLONAPHTHYRIDINE DERIVATIVE ASKA PHARM CO LTD (JP) 2011-09-14 EP claimed
US-20100093782-A1 Pyrazolonaphthyridine derivatives KANAZAWA HASHIME 2010-04-15 US claimed
US-20060040972-A1 Pyrazolonaphthyridine derivative ASKA PHARMACEUTICAL CO., LTD. (JP) 2006-02-23 US claimed
EP-1559716-A1 PYRAZOLONAPHTHYRIDINE DERIVATIVE Grelan Pharmaceutical Co., Ltd. (JP) 2005-08-03 EP claimed
EP-1559716-B1 PYRAZOLONAPHTHYRIDINE DERIVATIVE ASKA PHARM CO LTD (JP) 2011-09-14 EP disclosed
US-20100093782-A1 Pyrazolonaphthyridine derivatives KANAZAWA HASHIME 2010-04-15 US disclosed
US-7608716-B2 Pyrazolonaphthyridine derivative ASKA PHARMACEUTICAL CO., LTD. (JP) 2009-10-27 US disclosed
US-20060040972-A1 Pyrazolonaphthyridine derivative ASKA PHARMACEUTICAL CO., LTD. (JP) 2006-02-23 US disclosed
EP-1559716-A1 PYRAZOLONAPHTHYRIDINE DERIVATIVE Grelan Pharmaceutical Co., Ltd. (JP) 2005-08-03 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060040972-A1 Pyrazolonaphthyridine derivative PDE3B, PDE3A, PDE4A PDE1A 28/4885PDE1B 24/4885KMT2A 3171/4885
US-20100093782-A1 Pyrazolonaphthyridine derivatives PDE3B, PDE3A, PDE4A PDE1A 30/4885PDE1B 23/4885KMT2A 3015/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.